GlassScriptPhysician profile
Krishna K Chalasani
NPI 1427314202
$9,774.31
in general payments reported to CMS, 2019-2025
45 companies · $2,253 in 2025
The $2,253 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $282 · 2021: $1,046 · 2022: $1,089 · 2023: $2,403 · 2024: $2,061 · 2025: $2,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,717.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,730.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $1,400.41 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Corcept Therapeutics | $818.31 | 2019-2025 | Korlym |
| Lilly USA, LLC | $612.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $576.55 | 2019-2025 | |
| Amgen INC. | $550.62 | 2019-2025 | Evenity, Prolia, Tepezza |
| Dexcom, INC. | $521.61 | 2023-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $462.08 | 2021-2025 | Afrezza |
| Insulet Corporation | $281.87 | 2021-2025 | Omnipod |
| Abbvie INC. | $271.68 | 2023-2025 | Synthroid |
| Embecta Corp. | $248.59 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Astrazeneca Pharmaceuticals LP | $248.21 | 2019-2024 | Farxiga, Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.54 | 2019-2023 | Jardiance |
| Xeris Pharmaceuticals, INC. | $211.02 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Medtronic, INC. | $206.07 | 2021-2025 | Minimed 780g |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $162.60 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $136.70 | 2023-2025 | Unithroid |
| Recordati_rare_diseases_inc. | $129.23 | 2023-2025 | Isturisa, Signifor Lar |
| Tandem Diabetes Care, INC. | $101.33 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $86.11 | 2019-2025 | |
| Ucb, INC. | $80.52 | 2019-2023 | |
| Ibsa Pharma INC. | $78.84 | 2021-2024 | Licart, Tirosint |
| Alexion Pharmaceuticals, INC. | $66.24 | 2021-2025 | Strensiq |
| Merck Sharp & Dohme LLC | $56.99 | 2019-2025 | Pifeltro |
| Amryt Pharma Holdings LTD | $49.47 | 2022-2023 | Mycapssa |
| Chiesi USA, INC. | $41.20 | 2024-2025 | Mycapssa |
| Ipsen Biopharmaceuticals, INC | $38.02 | 2021-2023 | Somatuline Depot |
| Ionis Pharmaceuticals, INC. | $36.21 | 2025 | Tryngolza |
| Bayer Healthcare Pharmaceuticals INC. | $35.13 | 2023-2025 | |
| Ascendis Pharma Endocrinology INC | $34.36 | 2025 | Yorvipath |
| Almatica Pharma LLC | $31.19 | 2024 | Teriparatide |
| Amarin Pharma, INC. | $28.70 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $27.91 | 2020 | |
| Becton, Dickinson and Company | $27.59 | 2021-2022 | |
| Sequel Med Tech, LLC | $27.27 | 2025 | Twiist |
| Valeritas, INC. | $16.16 | 2019 | |
| Kyowa Kirin, INC. | $15.60 | 2024 | Crysvita |
| Rhythm Pharmaceuticals, INC. | $15.44 | 2025 | Imcivree |
| Sobi, INC | $14.98 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $14.80 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.75 | 2019 | |
| Clarus Therapeutics INC. | $14.62 | 2021 | |
| Cequr Corporation | $14.54 | 2023 | Cequr Simplicity |
| Aimmune Therapeutics, INC. | $12.98 | 2023 | |
| Celgene Corporation | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Chalasani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.